Claims for Patent: 6,150,337

Summary for Patent: 6,150,337

Title:	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
Abstract:	Ribavirin is employed in a manner which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin is used to suppress Type 2-mediated T cell responses and promote Type 1-mediated T cell response. Thus, instead of administering Ribavirin in its well-recognized role as an anti-viral agent, Ribavirin is herein used in the treatment of imbalances in lymphokine expression. Such imbalances may be found to be concomitants of allergic atopic disorders such as allergic asthma and atopic dermatitis, helminth infection and leishmaniasis, and various primary and secondary immunodeficiencies, which may or may not also be associated with viral infection.
Inventor(s):	Robert Tam
Assignee:	Bausch Health Americas Inc
Application Number:	US09/156,646
Patent Claims:	1. A method of inversely modulating Type 1 and Type 2 responses of lymphocytes contained within an environment by adding ribavirin to the lymphocytes in a concentration which increases the Type 1 response and suppresses the Type 2 response. 2. The method of claim 1 wherein the Type 2 response was previously elevated by an antigen. 3. The method of claim 1 wherein the Type 2 response was previously elevated by a helminth. 4. The method of claim 1 wherein the Type 2 response was previously elevated by an antibody. 5. A method of inhibiting a virus by growing a virus in an environment having lymphocytes which produce Type 1 and Type 2 cytokine responses, and adding ribavirin to the environment in a concentration which increases the Type 1 response and suppresses the Type 2 response. 6. The method of claim 1 wherein a patient has a drug induced impairment of immune function.